Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.

"Conflict-of-interest disclosure: J.S.A. reported receipt of personal fees from Celgene, Incyte, Takeda, Janssen, Genentech, Eli Lilly, Kite Pharma, AbbVie, AstraZeneca, Epizyme, Genmab, Century Therapeutics, Regeneron, MorphoSys, BeiGene, Mustang Bio, Ono Pharma, Kymera, bluebird bio, C4 Therapeutics, Caribou BioSciences, Interius, Cellectar, and Bristol Myers Squibb; and receipt of grants from Bristol Myers Squibb, Seattle Genetics, Mustang Bio, Cellectis, and Merck. The remaining authors declare no competing financial interests."

"The study is supported in part by the award number P30CA014089 (M.A.) from the 10.13039/100000054National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. T.Y. reported receiving personal fees from AbbVie outside of submitted work."